Assessing the role of the EGF receptor in the development and progression of pancreatic cancer

License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Gastrointestinal Cancer: Targets and Therapy 2014:4 23–37 Gastrointestinal Cancer: Targets and Therapy Dovepress

[1]  D. Hedley,et al.  Phase II trial of erlotinib in advanced pancreatic cancer (PC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Montagnini,et al.  Prognostic significance of epidermal growth factor receptor overexpression in pancreas cancer and nodal metastasis , 2015, ANZ journal of surgery.

[3]  P. Jänne,et al.  The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.

[4]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[5]  A. Sauvanet,et al.  EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins , 2013, Journal of Clinical Pathology.

[6]  D. Wheeler,et al.  Nuclear EGFR as a molecular target in cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  J. Pearson,et al.  Clinical and molecular characterization of HER2 amplified-pancreatic cancer , 2013, Genome Medicine.

[8]  N. Tebbutt,et al.  Targeting the ERBB family in cancer: couples therapy , 2013, Nature Reviews Cancer.

[9]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[10]  M. Choti,et al.  Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. , 2013, International journal of radiation oncology, biology, physics.

[11]  R. Salgia,et al.  Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. , 2013, Lung cancer.

[12]  Wenping Ding,et al.  Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis. , 2013, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[13]  D. Goldstein,et al.  Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  V. Heinemann,et al.  KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer , 2013, Journal of Gastroenterology.

[15]  R. López,et al.  Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study). , 2013, Anticancer research.

[16]  U. Mansmann,et al.  EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 , 2012, British Journal of Cancer.

[17]  M. Korc,et al.  Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  H. Crawford,et al.  KRAS above and beyond – EGFR in pancreatic cancer , 2012, Oncotarget.

[19]  G. Lopes,et al.  Phase II Study of Gemcitabine, Oxaliplatin, and Cetuximab in Advanced Pancreatic Cancer , 2012, American journal of clinical oncology.

[20]  Keunchil Park,et al.  Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Jens T Siveke,et al.  EGF receptor is required for KRAS-induced pancreatic tumorigenesis. , 2012, Cancer cell.

[22]  M. Barbacid,et al.  EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[23]  H. Lenz,et al.  A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma , 2012, Investigational New Drugs.

[24]  Gur Pines,et al.  The ERBB network: at last, cancer therapy meets systems biology , 2012, Nature Reviews Cancer.

[25]  H. Tsuda,et al.  Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma. , 2012, Experimental and therapeutic medicine.

[26]  M. Ducreux,et al.  O-0007 Exploratory Serum Biomarker Analyses from BO21129, a Phase II Study of Erlotinib in Second-Line Pancreatic Cancer: Potential Role of Amphiregulin? , 2012 .

[27]  Chiun Hsu,et al.  DOSE ESCALATION TO RASH FOR ERLOTINIB PLUS GEMCITABINE IN PATIENTS WITH METASTATIC PANCREATIC CANCER: THE PHASE II RACHEL (BO21128) STUDY , 2012 .

[28]  F. Lordick,et al.  Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer , 2012, Investigational New Drugs.

[29]  Y. Ko,et al.  Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104) , 2012, Gut.

[30]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[31]  C. Schmoor,et al.  Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer , 2012, British Journal of Cancer.

[32]  D. Richel,et al.  A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer , 2012, Investigational New Drugs.

[33]  I. Hwang,et al.  A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer , 2012, Investigational New Drugs.

[34]  Moorthy P Ponnusamy,et al.  Targeting the EGFR signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[35]  D. Wheeler,et al.  The nuclear epidermal growth factor receptor signaling network and its role in cancer. , 2011, Discovery medicine.

[36]  M. Sliwkowski,et al.  A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. , 2011, Cancer cell.

[37]  Joon-Oh Park,et al.  Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy , 2011, Molecular Cancer Therapeutics.

[38]  Jeffrey E. Lee,et al.  Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  F. Sarkar,et al.  A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer , 2011, Investigational New Drugs.

[40]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[41]  P. Yue,et al.  A Functional Nuclear Epidermal Growth Factor Receptor, Src and Stat3 Heteromeric Complex in Pancreatic Cancer Cells , 2011, PloS one.

[42]  A. Moser,et al.  Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer , 2011, Annals of Surgical Oncology.

[43]  S. Varadarajulu,et al.  A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer , 2011, Cancer Chemotherapy and Pharmacology.

[44]  E. Van Cutsem,et al.  Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. , 2011, The Lancet. Oncology.

[45]  D. Riese,et al.  Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. , 2011, Experimental cell research.

[46]  M. Tsao,et al.  Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer , 2010, Cancer.

[47]  L. Fei,et al.  Intraductal papillary mucinous neoplasms of the pancreas: diagnosis and management. , 2010, European journal of gastroenterology & hepatology.

[48]  P. Harari,et al.  Understanding resistance to EGFR inhibitors—impact on future treatment strategies , 2010, Nature Reviews Clinical Oncology.

[49]  G. V. Vande Woude,et al.  MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. , 2010, Cancer research.

[50]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[51]  A. Khorana,et al.  Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  F. Lordick,et al.  Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. , 2010, International journal of clinical pharmacology and therapeutics.

[53]  R. Kelley,et al.  A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer , 2010, Cancer Chemotherapy and Pharmacology.

[54]  F. Ali-Osman,et al.  Cyclooxygenase-2 Is a Novel Transcriptional Target of the Nuclear EGFR-STAT3 and EGFRvIII-STAT3 Signaling Axes , 2010, Molecular Cancer Research.

[55]  D. Wheeler,et al.  Nuclear EGFR contributes to acquired resistance to cetuximab , 2009, Oncogene.

[56]  A. Bardelli,et al.  Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer , 2009, Journal of the National Cancer Institute.

[57]  P. V. van Diest,et al.  HER-family gene amplification and expression in resected pancreatic cancer. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[58]  M. Hung,et al.  Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer , 2009, Molecular carcinogenesis.

[59]  K. Wakasa,et al.  HER2 overexpression correlates with survival after curative resection of pancreatic cancer , 2009, Cancer science.

[60]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[61]  Y. Bang,et al.  A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research , 2009, Investigational New Drugs.

[62]  W. Scheithauer,et al.  Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  A. Hinke,et al.  Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study , 2009, British Journal of Cancer.

[64]  J. Schlesselman,et al.  Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer , 2009, Oncology.

[65]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[66]  Gordon C Jayson,et al.  Angiogenesis as a therapeutic target in cancer. , 2008, Clinical medicine.

[67]  D. Yee,et al.  Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. , 2008, The Journal of clinical investigation.

[68]  B. Bereczky,et al.  Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line , 2008, Molecular Cancer.

[69]  M. Hung,et al.  Survival of cancer cells is maintained by EGFR independent of its kinase activity. , 2008, Cancer cell.

[70]  Manuel Hidalgo,et al.  Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. , 2008, Cancer research.

[71]  G. Tortora,et al.  Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs , 2008, British Journal of Cancer.

[72]  A. Kemona,et al.  Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. , 2008, Anticancer research.

[73]  N. Normanno,et al.  The role of the EGFR signaling in tumor microenvironment , 2008, Journal of cellular physiology.

[74]  George Fountzilas,et al.  Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation , 2008, Cancer investigation.

[75]  Eric T. Sawey,et al.  Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway , 2007, Proceedings of the National Academy of Sciences.

[76]  V. Georgoulias,et al.  A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer , 2007, Oncology.

[77]  R. Hruban,et al.  Tumorigenesis and Neoplastic Progression Acinar Cells Contribute to the Molecular Heterogeneity of Pancreatic Intraepithelial Neoplasia , 2007 .

[78]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  M. Heslin,et al.  Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer , 2007 .

[80]  M. Hung,et al.  Nuclear‐cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1 , 2006, Journal of cellular biochemistry.

[81]  A. Bhardwaj,et al.  Epidermal Growth Factor Receptor Expression in Pancreatic Carcinoma Using Tissue Microarray Technique , 2006, Digestive Surgery.

[82]  Janusz Jankowski,et al.  Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas , 2006, Clinical Cancer Research.

[83]  H. Tsuda,et al.  Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer , 2006, Modern Pathology.

[84]  Ralph Weissleder,et al.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[85]  A. Molven,et al.  Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes , 2006, Virchows Archiv.

[86]  R. Hruban,et al.  Molecular pathogenesis of pancreatic cancer. , 2006, Annual review of genomics and human genetics.

[87]  M. Hung,et al.  EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization , 2006, Breast Cancer Research and Treatment.

[88]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[89]  S. Leach,et al.  Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates , 2005, Development.

[90]  D. Rimm,et al.  Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis , 2005, Clinical Cancer Research.

[91]  Sheng-Chieh Hsu,et al.  Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.

[92]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[93]  M. Iorio,et al.  Role of HER receptors family in development and differentiation , 2004, Journal of cellular physiology.

[94]  R. Wolff,et al.  Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[96]  D. Iannitti,et al.  Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu , 2004 .

[97]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[98]  J. Cameron,et al.  Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray , 2003, Modern Pathology.

[99]  Masato Nakamura,et al.  Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. , 2003, International journal of molecular medicine.

[100]  D. Iannitti,et al.  Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma , 2001, American journal of clinical oncology.

[101]  K. Makino,et al.  Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.

[102]  T. Mattfeldt,et al.  A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. , 2001, Genes & development.

[103]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[104]  I. Fidler,et al.  Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. , 2000, Cancer research.

[105]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  H. Friess,et al.  ErbB‐4 mRNA expression is decreased in non‐metastatic pancreatic cancer , 1999, International journal of cancer.

[107]  Y. Nio,et al.  Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. , 1997, Anticancer research.

[108]  W. Kabsch,et al.  The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. , 1997, Science.

[109]  M. Korc,et al.  Overexpression of transforming growth factor-alpha and epidermal growth factor receptor, but not epidermal growth factor, in exocrine pancreatic tumours in hamsters. , 1996, Carcinogenesis.

[110]  S. Goodman,et al.  Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. , 1996, Human pathology.

[111]  H. Friess,et al.  Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[112]  B. Nakata,et al.  Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival , 1995, International journal of pancreatology : official journal of the International Association of Pancreatology.

[113]  R. Hruban,et al.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. , 1994, Cancer research.

[114]  H. Friess,et al.  Overexpression of HER2/neu oncogene in human pancreatic carcinoma. , 1993, Human pathology.

[115]  Y. Yamanaka.  The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer. , 1992, Nihon Ika Daigaku zasshi.

[116]  R. Palmiter,et al.  Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast , 1990, Cell.

[117]  G. Merlino,et al.  TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas , 1990, Cell.

[118]  G. Fleuren,et al.  KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. , 1988, Nucleic acids research.

[119]  A. Pandiella,et al.  HER3 Overexpression and Survival in Solid Tumors , 2012 .

[120]  D. Moore,et al.  Randomized phase II trial of panitumumab (P), erlotinib (E), and gemcitabine (G) versus erlotinib-gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  J. Feliu,et al.  Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer , 2010, Cancer Chemotherapy and Pharmacology.

[122]  J. Shipley,et al.  Lapatinib and gemcitabine for metastatic pancreatic cancer: A phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  Michael Goggins,et al.  Update on pancreatic intraepithelial neoplasia. , 2008, International journal of clinical and experimental pathology.

[124]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[125]  S. Barni,et al.  Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. , 2008, The Lancet. Oncology.

[126]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[127]  H. Juhl,et al.  Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. , 2001, International journal of surgical investigation.

[128]  National Cancer Institute of Canada Clinical Trials Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[129]  H. Friess,et al.  Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. , 1993, Anticancer research.

[130]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[131]  B. Burtness,et al.  Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Treatment of Pancreatic Cancer with Epidermal Growth Factor Receptor-targeted Therapy , 2022 .